Floatz logo

15 assets in Ureter Transitional Cell Carcinoma

Therapeutic assets addressing Ureter Transitional Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Nivolumab
Ureter Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3BB (68)
Cyclophosphamide
Ureter Transitional Cell Carcinoma
Fred Hutchinson Cancer CenterP3BB (67)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Ureter Transitional Cell Carcinoma
Fred Hutchinson Cancer CenterP2BB (65)
Pembrolizumab
Ureter Transitional Cell Carcinoma
Fred Hutchinson Cancer CenterP3BB (65)
Atezolizumab
Ureter Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3B (62)
Durvalumab
Ureter Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3B (60)
Relatlimab
Ureter Transitional Cell Carcinoma
M.D. Anderson Cancer CenterP2B (60)
Ipilimumab
Ureter Transitional Cell Carcinoma
M.D. Anderson Cancer CenterP2B (59)
Avelumab
Ureter Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3B (57)
Apsolol
Ureter Transitional Cell Carcinoma
Emory UniversityP2CCC (53)
Eribulin Monomethanesulfonate
Ureter Transitional Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Tocilizumab
Ureter Transitional Cell Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Quemliclustat
Ureter Transitional Cell Carcinoma
Fred Hutchinson Cancer CenterP1/2CC (47)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Ureter Transitional Cell Carcinoma
National Cancer Institute (NCI)P1CC (43)